220 related articles for article (PubMed ID: 23929215)
21. Dnmt3a is downregulated by Stat5a and mediates G0/G1 arrest by suppressing the miR-17-5p/Cdkn1a axis in Jak2
Zhou J; Guo C; Wu H; Li B; Zhou LL; Liang AB; Fu JF
BMC Cancer; 2021 Nov; 21(1):1213. PubMed ID: 34773997
[TBL] [Abstract][Full Text] [Related]
22. Three Tyrosine Residues in the Erythropoietin Receptor Are Essential for Janus Kinase 2 V617F Mutant-induced Tumorigenesis.
Ueda F; Tago K; Tamura H; Funakoshi-Tago M
J Biol Chem; 2017 Feb; 292(5):1826-1846. PubMed ID: 27998978
[TBL] [Abstract][Full Text] [Related]
23. Co-targeting the PI3K/mTOR and JAK2 signalling pathways produces synergistic activity against myeloproliferative neoplasms.
Bartalucci N; Tozzi L; Bogani C; Martinelli S; Rotunno G; Villeval JL; Vannucchi AM
J Cell Mol Med; 2013 Nov; 17(11):1385-96. PubMed ID: 24237791
[TBL] [Abstract][Full Text] [Related]
24. Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
Tibes R; Mesa RA
Leuk Lymphoma; 2011 Jul; 52(7):1178-87. PubMed ID: 21599574
[TBL] [Abstract][Full Text] [Related]
25. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.
Tyner JW; Bumm TG; Deininger J; Wood L; Aichberger KJ; Loriaux MM; Druker BJ; Burns CJ; Fantino E; Deininger MW
Blood; 2010 Jun; 115(25):5232-40. PubMed ID: 20385788
[TBL] [Abstract][Full Text] [Related]
26. Suppression of multiple anti-apoptotic BCL2 family proteins recapitulates the effects of JAK2 inhibitors in JAK2V617F driven myeloproliferative neoplasms.
Takei H; Coelho-Silva JL; Tavares Leal C; Queiroz Arantes Rocha A; Mantello Bianco T; Welner RS; Mishima Y; Kobayashi IS; Mullally A; Lima K; Machado-Neto JA; Kobayashi SS; Lobo de Figueiredo-Pontes L
Cancer Sci; 2022 Feb; 113(2):597-608. PubMed ID: 34808021
[TBL] [Abstract][Full Text] [Related]
27. Dual PI3K/AKT/mTOR inhibitor BEZ235 synergistically enhances the activity of JAK2 inhibitor against cultured and primary human myeloproliferative neoplasm cells.
Fiskus W; Verstovsek S; Manshouri T; Smith JE; Peth K; Abhyankar S; McGuirk J; Bhalla KN
Mol Cancer Ther; 2013 May; 12(5):577-88. PubMed ID: 23445613
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of WWQ-131, a highly selective JAK2 inhibitor, in mouse models of myeloproliferative neoplasms.
Ge H; Wang C; Tian C; Diao Y; Wang W; Ma X; Zhang J; Li H; Zhao Z; Zhu L
Biomed Pharmacother; 2022 Dec; 156():113884. PubMed ID: 36306591
[TBL] [Abstract][Full Text] [Related]
29. The HDAC inhibitor Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells.
Amaru Calzada A; Todoerti K; Donadoni L; Pellicioli A; Tuana G; Gatta R; Neri A; Finazzi G; Mantovani R; Rambaldi A; Introna M; Lombardi L; Golay J;
Exp Hematol; 2012 Aug; 40(8):634-45.e10. PubMed ID: 22579713
[TBL] [Abstract][Full Text] [Related]
30. Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival.
Rubert J; Qian Z; Andraos R; Guthy DA; Radimerski T
BMC Cancer; 2011 Jan; 11():24. PubMed ID: 21247487
[TBL] [Abstract][Full Text] [Related]
31. [Effect of IFN-α2b on COX-2 and Angiogenesis in JAK2V617F Mutation Myeloproliferative Neoplasms].
Zhao YL; Zhang LJ; Fu JZ; Xu Q; Liu GM; Xie XL; Liang WT; Cheng ZY
Sichuan Da Xue Xue Bao Yi Xue Ban; 2016 Jul; 47(4):473-478. PubMed ID: 28591945
[TBL] [Abstract][Full Text] [Related]
32. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
Pardanani A; Lasho T; Smith G; Burns CJ; Fantino E; Tefferi A
Leukemia; 2009 Aug; 23(8):1441-5. PubMed ID: 19295546
[TBL] [Abstract][Full Text] [Related]
33. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
Quintás-Cardama A; Vaddi K; Liu P; Manshouri T; Li J; Scherle PA; Caulder E; Wen X; Li Y; Waeltz P; Rupar M; Burn T; Lo Y; Kelley J; Covington M; Shepard S; Rodgers JD; Haley P; Kantarjian H; Fridman JS; Verstovsek S
Blood; 2010 Apr; 115(15):3109-17. PubMed ID: 20130243
[TBL] [Abstract][Full Text] [Related]
34. Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms.
Atallah E; Verstovsek S
Expert Rev Anticancer Ther; 2009 May; 9(5):663-70. PubMed ID: 19445582
[TBL] [Abstract][Full Text] [Related]
35. Clinical and laboratory significance of defective P2Y(12) pathway function in patients with myeloproliferative neoplasms: a pilot study.
Chang H; Shih LY; Michelson AD; Dunn P; Frelinger AL; Wang PN; Kuo MC; Lin TL; Wu JH; Tang TC
Acta Haematol; 2013; 130(3):181-7. PubMed ID: 23751441
[TBL] [Abstract][Full Text] [Related]
36. Addiction to DUSP1 protects JAK2V617F-driven polycythemia vera progenitors against inflammatory stress and DNA damage, allowing chronic proliferation.
Stetka J; Vyhlidalova P; Lanikova L; Koralkova P; Gursky J; Hlusi A; Flodr P; Hubackova S; Bartek J; Hodny Z; Divoky V
Oncogene; 2019 Jul; 38(28):5627-5642. PubMed ID: 30967632
[TBL] [Abstract][Full Text] [Related]
37. The cell cycle regulator CDC25A is a target for JAK2V617F oncogene.
Gautier EF; Picard M; Laurent C; Marty C; Villeval JL; Demur C; Delhommeau F; Hexner E; Giraudier S; Bonnevialle N; Ducommun B; Récher C; Laurent G; Manenti S; Mansat-De Mas V
Blood; 2012 Feb; 119(5):1190-9. PubMed ID: 22065597
[TBL] [Abstract][Full Text] [Related]
38. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression.
Marty C; Lacout C; Droin N; Le Couédic JP; Ribrag V; Solary E; Vainchenker W; Villeval JL; Plo I
Leukemia; 2013 Nov; 27(11):2187-95. PubMed ID: 23558526
[TBL] [Abstract][Full Text] [Related]
39. The PIM inhibitor AZD1208 synergizes with ruxolitinib to induce apoptosis of ruxolitinib sensitive and resistant JAK2-V617F-driven cells and inhibit colony formation of primary MPN cells.
Mazzacurati L; Lambert QT; Pradhan A; Griner LN; Huszar D; Reuther GW
Oncotarget; 2015 Nov; 6(37):40141-57. PubMed ID: 26472029
[TBL] [Abstract][Full Text] [Related]
40. IL-6 stimulation of DNA replication is JAK1/2 mediated in cross-talk with hyperactivated ERK1/2 signaling.
Subotički T; Mitrović Ajtić O; Beleslin-Čokić BB; Bjelica S; Djikić D; Diklić M; Leković D; Gotić M; Santibanez JF; Noguchi CT; Čokić VP
Cell Biol Int; 2019 Feb; 43(2):192-206. PubMed ID: 30571852
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]